Insurers are Pulling Back on MA. How Does this Affect Patients?
Many insurers seem to be retreating from Medicare Advantage by exiting unprofitable markets and reducing benefits. This could be extremely disruptive to patients, experts warn.
Analysis: The No Good, Very Bad Year for UnitedHealth
UnitedHealth Group has had a difficult year marked by a dramatic stock drop, leadership shake-up and mounting regulatory scrutiny. Experts point to its aggressive Medicare Advantage strategy and a rapidly evolving healthcare landscape as key drivers of its challenges.
presented by
The Top Appointment Scheduling Software for Wellness Clinics
Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.
Why UnitedHealth Group’s Shares Have Taken a Tumble
UnitedHealth Group's shares fell by over 22% on Thursday after its first quarter earnings. This is largely due to challenges in its Medicare Advantage business.
The Big 3 PBMs are Countersuing the FTC. Does Their Argument Have Any Teeth?
After the FTC filed a lawsuit in September, accusing the three major pharmacy benefit managers of anticompetitive rebating practices related to insulin, the defendants reversed roles and became plaintiffs. In November, they countersued the agency, arguing that its lawsuit is unconstitutional.
Why the DOJ’s Lawsuit Against the UGH-Amedisys Merger May Not Go Anywhere
Experts aren’t sure what the outcome of the DOJ’s recent lawsuit against the proposed UnitedHealth Group/Amedisys merger will be under the incoming Trump administration. The Biden administration has focused more on supporting clinicians, while the previous Trump administration favored corporations. Additionally, one expert noted that this case differs from other antitrust lawsuits because it does not seem to focus on a potential price increase.